Archive · 12 Aug 2025
Vinay Prasad Returns to FDA as Vaccine Chief After Backlash
Imagine a doctor who helps decide which medicines are safe.
This doctor, Dr. Prasad, was in charge of vaccines but was recently asked to leave because some people disagreed with his decisions.
These people included activists and supporters of faster medicine approvals.
They didn't like his past comments or his decision to temporarily stop a gene therapy.
However, Dr. Prasad is now returning to his job.
He had support from other leaders in the FDA who wanted to carefully review COVID-19 vaccines.
During his previous time, the FDA made it harder to approve new COVID-19 vaccines.
Dr. Vinay Prasad is returning as the FDA's top vaccine regulator.
Prasad previously stepped down after facing criticism from right-wing activists and others.
He faced scrutiny due to past criticisms of Trump and decisions on drug approvals.
Prasad had support from FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr.
During his tenure, the FDA restricted approvals for certain COVID-19 vaccines.
- Who
- Dr. Vinay Prasad, a Food and Drug Administration official.
- What
- Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies.
- When
- Monday, after leaving the agency late last month.
- Where
- At the FDA.
- Why
- The reason for his return isn't explicitly stated, but he had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr.
Critics of Prasad
Supporters of Prasad
Prasad's Ideology
Critics of Prasad
Prasad was a 'progressive leftist saboteur' and unfit to lead.
Supporters of Prasad
N/A
Prasad's Decision on Gene Therapy
Critics of Prasad
Prasad's decision to pause a gene therapy was incorrect and hindered patient access.
Supporters of Prasad
N/A
- Official
- Dr. Vinay Prasad
- Role
- FDA's top vaccine regulator
- Reason for Departure
- Pressure from activists and others
- Support
- FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr.
- Controversy
- Criticisms of Trump and drug approval decisions